Mostrar el registro sencillo del ítem

dc.contributor.authorVigon-Hernandez, Lorena 
dc.contributor.authorGarcía-Pérez, Javier 
dc.contributor.authorRodríguez-Mora, Sara 
dc.contributor.authorTorres, Montserrat 
dc.contributor.authorMateos, Elena 
dc.contributor.authorCastillo de la Osa, María 
dc.contributor.authorCervero, Miguel
dc.contributor.authorMalo De Molina, Rosa
dc.contributor.authorNavarro, Cristina
dc.contributor.authorMurciano-Antón, María Aránzazu
dc.contributor.authorGarcía-Gutiérrez, Valentín
dc.contributor.authorPlanelles, Vicente
dc.contributor.authorAlcamí, José 
dc.contributor.authorPerez-Olmeda, Mayte 
dc.contributor.authorCoiras, Mayte 
dc.contributor.authorLopez-Huertas, Maria Rosa 
dc.contributor.authorMultidisciplinary Group of Study of COVID-19 (MGS-COVID)
dc.date.accessioned2022-05-05T09:24:06Z
dc.date.available2022-05-05T09:24:06Z
dc.date.issued2021-09
dc.identifier.citationFront Immunol. 2021 Sep 20;12:742631.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14259
dc.description.abstractSARS-CoV-2 infection causes COVID-19, ranging from mild to critical disease in symptomatic subjects. It is essential to better understand the immunologic responses occurring in patients with the most severe outcomes. In this study, parameters related to the humoral immune response elicited against SARS-CoV-2 were analysed in 61 patients with different presentations of COVID-19 who were recruited in Hospitals and Primary Healthcare Centres in Madrid, Spain, during the first pandemic peak between April and June 2020. Subjects were allocated as mild patients without hospitalization, severe patients hospitalized or critical patients requiring ICU assistance. Critical patients showed significantly enhanced levels of B cells with memory and plasmablast phenotypes, as well as higher levels of antibodies against SARS-CoV-2 with neutralization ability, which were particularly increased in male gender. Despite all this, antibody-dependent cell-mediated cytotoxicity was defective in these individuals. Besides, patients with critical COVID-19 also showed increased IgG levels against herpesvirus such as CMV, EBV, HSV-1 and VZV, as well as detectable CMV and EBV viremia in plasma. Altogether, these results suggest an enhanced but ineffectual immune response in patients with critical COVID-19 that allowed latent herpesvirus reactivation. These findings should be considered during the clinical management of these patients due to the potential contribution to the most severe disease during SARS-CoV-2 infection.es_ES
dc.description.sponsorshipThis work was supported by the Coordinated Research Activities at the Centro Nacional de Microbiología (CNM, Instituto de Salud Carlos III) (COV20_00679) to promote an integrated response against SARS-CoV-2 in Spain (Spanish Ministry of Science and Innovation) that is coordinated by Dr Inmaculada Casas (WHO National Influenza Center of the CNM) and a generous donation provided by Chiesi España, S.A.U. (Barcelona, Spain). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. This work was also supported by the Spanish Ministry of Economy and Competitiveness (PID2019 110275RB-I00); the Spanish AIDS Research Network RD16CIII/0002/0001 that is included in Acción Estratégica en Salud, Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica 2016-2020, Instituto de Salud Carlos III, European Region Development Fund (ERDF); Miguel Servet - AESI, MPY 341/21. The work of ML-H and SR is financed by NIH grant R01AI143567. The work of MT is supported by Instituto de Salud Carlos III (COV20_00679). The work of LV is supported by a predoctoral grant from Instituto de Salud Carlos III (FIS PI16CIII/00034-ISCIII-FEDER).es_ES
dc.language.isoenges_ES
dc.publisherFrontiers Media es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCMV reactivationes_ES
dc.subjectCOVID-19 severityes_ES
dc.subjectEBV reactivationes_ES
dc.subjectSARS-CoV-2 neutralizing antibodieses_ES
dc.subjectAntibody-dependent cellular cytotoxicity (ADCC)es_ES
dc.subjectHumoral responsees_ES
dc.titleImpaired Antibody-Dependent Cellular Cytotoxicity in a Spanish Cohort of Patients With COVID-19 Admitted to the ICUes_ES
dc.typeresearch articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID34616404es_ES
dc.format.volume12es_ES
dc.format.page742631es_ES
dc.identifier.doi10.3389/fimmu.2021.742631es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España) es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España) es_ES
dc.contributor.funderRed de Investigación Cooperativa en Investigación en Sida (España) es_ES
dc.contributor.funderPlan Nacional de I+D+i (España) es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) es_ES
dc.contributor.funderNational Institutes of Health (Estados Unidos) es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1664-3224es_ES
dc.relation.publisherversionhttps://doi.org/10.3389/fimmu.2021.742631es_ES
dc.identifier.journalFrontiers in Immunologyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2019110275RB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RD16CIII/0002/0001es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/COV20_00679es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI16CIII/00034-ISCIII-FEDERes_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/MPY341/21es_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional